JP2019514976A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019514976A5 JP2019514976A5 JP2018558274A JP2018558274A JP2019514976A5 JP 2019514976 A5 JP2019514976 A5 JP 2019514976A5 JP 2018558274 A JP2018558274 A JP 2018558274A JP 2018558274 A JP2018558274 A JP 2018558274A JP 2019514976 A5 JP2019514976 A5 JP 2019514976A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- anesthetic
- particles
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 35
- 230000003444 anaesthetic effect Effects 0.000 claims description 25
- XPXMKIXDFWLRAA-UHFFFAOYSA-N hydrazinide Chemical compound [NH-]N XPXMKIXDFWLRAA-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 14
- 239000002609 medium Substances 0.000 claims description 13
- 239000012453 solvate Substances 0.000 claims description 12
- 239000004034 viscosity adjusting agent Substances 0.000 claims description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
- 239000004094 surface-active agent Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 7
- 229920000642 polymer Polymers 0.000 claims description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 6
- 230000036592 analgesia Effects 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 claims description 5
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 5
- JJTUDXZGHPGLLC-UHFFFAOYSA-N lactide Chemical compound CC1OC(=O)C(C)OC1=O JJTUDXZGHPGLLC-UHFFFAOYSA-N 0.000 claims description 5
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 5
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 5
- 239000000872 buffer Substances 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 239000006184 cosolvent Substances 0.000 claims description 3
- 229960003964 deoxycholic acid Drugs 0.000 claims description 3
- 235000019441 ethanol Nutrition 0.000 claims description 3
- 235000011187 glycerol Nutrition 0.000 claims description 3
- 150000004677 hydrates Chemical class 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 3
- 229940068977 polysorbate 20 Drugs 0.000 claims description 3
- 229920000053 polysorbate 80 Polymers 0.000 claims description 3
- 229940068968 polysorbate 80 Drugs 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims description 3
- 239000012929 tonicity agent Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 claims description 2
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 claims description 2
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 claims description 2
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 2
- 239000012736 aqueous medium Substances 0.000 claims description 2
- 229960003831 articaine Drugs 0.000 claims description 2
- 229960003150 bupivacaine Drugs 0.000 claims description 2
- 229960001747 cinchocaine Drugs 0.000 claims description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229960003976 etidocaine Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 230000008595 infiltration Effects 0.000 claims description 2
- 238000001764 infiltration Methods 0.000 claims description 2
- 229960004288 levobupivacaine Drugs 0.000 claims description 2
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 claims description 2
- 229960004194 lidocaine Drugs 0.000 claims description 2
- 229960002409 mepivacaine Drugs 0.000 claims description 2
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 claims description 2
- 229960001807 prilocaine Drugs 0.000 claims description 2
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 claims description 2
- 230000002035 prolonged effect Effects 0.000 claims description 2
- 229960001549 ropivacaine Drugs 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 description 5
- 230000001953 sensory effect Effects 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 229940083542 sodium Drugs 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662332015P | 2016-05-05 | 2016-05-05 | |
| US62/332,015 | 2016-05-05 | ||
| US201662440088P | 2016-12-29 | 2016-12-29 | |
| US62/440,088 | 2016-12-29 | ||
| US201762443318P | 2017-01-06 | 2017-01-06 | |
| US62/443,318 | 2017-01-06 | ||
| US201762463206P | 2017-02-24 | 2017-02-24 | |
| US62/463,206 | 2017-02-24 | ||
| US201762472885P | 2017-03-17 | 2017-03-17 | |
| US62/472,885 | 2017-03-17 | ||
| PCT/US2017/031397 WO2017193066A1 (en) | 2016-05-05 | 2017-05-05 | Precision controlled load and release particles for post-operative pain |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019514976A JP2019514976A (ja) | 2019-06-06 |
| JP2019514976A5 true JP2019514976A5 (enExample) | 2020-06-18 |
Family
ID=60203445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018558274A Pending JP2019514976A (ja) | 2016-05-05 | 2017-05-05 | 負荷と放出が正確に制御された術後疼痛用粒子 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20190209538A1 (enExample) |
| EP (1) | EP3452031A4 (enExample) |
| JP (1) | JP2019514976A (enExample) |
| WO (1) | WO2017193066A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021146215A1 (en) | 2020-01-13 | 2021-07-22 | Durect Corporation | Sustained release drug delivery systems with reduced impurities and related methods |
| CN116669717A (zh) * | 2020-08-17 | 2023-08-29 | 美国人福制药公司 | 长效原位成型/胶凝组合物 |
| CA3203561A1 (en) | 2021-01-12 | 2022-07-21 | Adrian Neil Verity | Sustained release drug delivery systems and related methods |
| TW202308595A (zh) * | 2021-08-13 | 2023-03-01 | 大陸商江西濟民可信集團有限公司 | 一種微球懸液、微粒製劑及其製備方法 |
| JP7768735B2 (ja) * | 2021-11-16 | 2025-11-12 | 新田ゼラチン株式会社 | 生体吸収性粒子 |
| WO2025015011A1 (en) * | 2023-07-10 | 2025-01-16 | Nevakar Injectables Inc. | Bupivacaine compositions and methods |
| US12648940B2 (en) | 2023-09-12 | 2026-06-09 | Fresenius Kabi Austria Gmbh | Bupivacaine liquid formulations |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922340A (en) * | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
| AU733867B2 (en) * | 1996-06-24 | 2001-05-31 | Euro-Celtique S.A. | Methods for providing safe local anesthesia |
| US6046187A (en) * | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
| IL129951A0 (en) * | 1997-07-02 | 2000-02-29 | Euro Celtique Sa | Prolonged anesthesia in joints and body spaces |
| US7582311B1 (en) * | 1999-10-15 | 2009-09-01 | Genentech, Inc. | Injection vehicle for polymer-based formulations |
| WO2002032398A2 (en) * | 2000-10-16 | 2002-04-25 | Massachusetts Institute Of Technology | Lipid-protein-sugar particles for drug delivery |
| US20030152637A1 (en) * | 2001-01-25 | 2003-08-14 | Mark Chasin | Local anesthetic, and method of use |
| US8986736B2 (en) * | 2003-06-24 | 2015-03-24 | Baxter International Inc. | Method for delivering particulate drugs to tissues |
| US20050106214A1 (en) * | 2003-11-14 | 2005-05-19 | Guohua Chen | Excipients in drug delivery vehicles |
| US20060127468A1 (en) * | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
| DK2767292T3 (en) * | 2004-09-17 | 2016-12-19 | Durect Corp | RENEWABLE local anesthetic COMPOSITION CONTAINING SAIB |
| CA2611985C (en) * | 2005-06-17 | 2016-08-16 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials |
| WO2008063204A2 (en) * | 2006-01-27 | 2008-05-29 | The University Of North Carolina At Chapel Hill | Taggants and methods and systems for fabricating |
| US20080102123A1 (en) * | 2006-10-27 | 2008-05-01 | Schachter Deborah M | Self-gelling tunable drug delivery system |
| US8846068B2 (en) * | 2008-04-18 | 2014-09-30 | Warsaw Orthopedic, Inc. | Methods and compositions for treating post-operative pain comprising a local anesthetic |
| WO2009132153A2 (en) * | 2008-04-22 | 2009-10-29 | Angiotech Pharmaceuticals, Inc. | Biocompatible crosslinked hydrogels, drug-loaded hydrogels and methods of using the same |
| WO2012075447A2 (en) * | 2010-12-03 | 2012-06-07 | Warsaw Orthopedic, Inc. | Compositions and methods for delivering clonidine and bupivacaine to a target tissue site |
| US10188772B2 (en) * | 2011-10-18 | 2019-01-29 | Micell Technologies, Inc. | Drug delivery medical device |
| BR112015015439A2 (pt) * | 2012-12-28 | 2017-07-11 | Otsuka Pharma Co Ltd | formulação injetável depot, processo para produzir uma formulação injetável depot, e, kit para prevenção ou tratamento de doença renal policística, uso de uma combinação |
| JP6723162B2 (ja) * | 2014-04-21 | 2020-07-15 | ヘロン セラピューティクス， インコーポレイテッドＨｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ポリオルトエステルおよび有機酸添加剤の組成物 |
| WO2015164840A1 (en) * | 2014-04-24 | 2015-10-29 | Georgia Tech Research Corporation | Microneedles and methods of manufacture thereof |
-
2017
- 2017-05-05 WO PCT/US2017/031397 patent/WO2017193066A1/en not_active Ceased
- 2017-05-05 US US16/099,118 patent/US20190209538A1/en not_active Abandoned
- 2017-05-05 JP JP2018558274A patent/JP2019514976A/ja active Pending
- 2017-05-05 EP EP17793498.1A patent/EP3452031A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200970348A1 (ru) | Новые инъецируемые депо-композиции и способ получения таких композиций | |
| JP2014040474A (ja) | ３種のポリマーの相乗的組み合わせを含む眼科用組成物 | |
| JP2015511241A5 (enExample) | ||
| JP2004521111A5 (enExample) | ||
| JP2016513721A5 (enExample) | ||
| AU2014251532B2 (en) | Tadalafil free base-containing film dosage form containing polyethylene glycol-based polymer and/or vinyl pyrrolidone-based polymer as dispersion stabilizer | |
| JP2013519705A5 (enExample) | ||
| BRPI0714712A2 (pt) | dispositivos de distribuiÇço transmucosal com absorÇço intensificada | |
| JP2002363097A5 (enExample) | ||
| JP2016513721A (ja) | 高薬物含有ブプレノルフィンマイクロスフェア及びその製造方法 | |
| JP2013518097A (ja) | 肺高血圧を予防および治療するための組成物および方法 | |
| CN103961702A (zh) | 粘膜给予用wt1肽癌症疫苗组合物 | |
| ES2895764T3 (es) | Dispositivo de microagujas | |
| RU2535089C2 (ru) | Суспензия и затвердевшая композиция, содержащие производное карбостирила и силиконовое масло и/или производное силиконового масла | |
| AR079654A1 (es) | Combinaciones anticancerosas de farmacos a base de artemisinina y otros agentes quimioterapeuticos. uso. composicion farmaceutica. procedimiento de preparacion. metodo de tratamiento. | |
| BRPI0406674B1 (pt) | composição para a ministração intranasal de fentanila ou um seu sal farmaceuticamente aceitável, uso de uma composição, dispositivo para pulverização, e, processo para preparar uma composição | |
| KR20090057400A (ko) | 트롬빈 수용체 길항제의 동결건조된 신속 붕해성 경구 제형 | |
| JP2009544665A5 (enExample) | ||
| CN103732218A (zh) | 类维生素a化合物至皮脂腺的靶向递送 | |
| MX2024004438A (es) | Inhibidores de integrinas y usos de los mismos en combinacion con otros agentes. | |
| HRP20201696T1 (hr) | Farmaceutska parenteralna formulacija koja sadrži kargluminsku kiselinu | |
| JP2011037849A (ja) | 消化性潰瘍及び十二指腸潰瘍の治療及び予防に使用されるヒアルロン酸混合物 | |
| PE20051049A1 (es) | Composiciones farmaceuticas que comprenden un antagonista de neuroquinina nk1 | |
| JP2018509473A (ja) | ポリマーの水溶液 | |
| RU2012116085A (ru) | Наночастицы оксалиплатина и способ их получения |